Apolo, A. B., Infante, J. R., Hamid, O., Patel, M. R., Wang, D., Kelly, K., … Gulley, J. L. (2016). Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression. In Journal of Clinical Oncology (Vol. 34, pp. 4514–4514). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.4514

Apolo, Andrea B., Jeffrey R. Infante, Omid Hamid, Manish R. Patel, Ding Wang, Karen Kelly, Anthony E. Mega, et al. “Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.” In Journal of Clinical Oncology, 34:4514–4514. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.4514.

Apolo AB, Infante JR, Hamid O, Patel MR, Wang D, Kelly K, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 4514–4514.

Apolo, Andrea B., et al. “Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 4514–4514. Crossref, doi:10.1200/jco.2016.34.15_suppl.4514.

Apolo AB, Infante JR, Hamid O, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, Safran H, Stinchcombe T, Grote HJ, von Heydebreck A, Cuillerot J-M, Gulley JL. Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 4514–4514.